By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CSL Behring 

1020 First Avenue
P.O. Box 61501
King of Prussia  Pennsylvania  19406-0901  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009



Company News
CSL Behring And Its Employees Pass $1 Million Mark In Charitable Donations To Communities Throughout The U.S. 2/2/2016 10:04:04 AM
CSL Behring Submits Marketing Authorization Application To The European Medicines Agency For RViii-SingleChain For Patients With Hemophilia A 12/22/2015 7:40:08 AM
CSL Behring Submits New Drug Application To Japan's Pharmaceuticals And Medical Devices Agency For rIX-FP For Hemophilia B Patients 12/21/2015 7:50:12 AM
CSL Behring Expands Operations To Russia 12/8/2015 12:14:25 PM
CSL Behring Presents Phase III Data for Its Long-Acting Recombinant Factor IX Albumin Fusion Protein for Hemophilia B at the 57th American Society of Hematology Annual Meeting & Exposition 12/7/2015 9:23:47 AM
CSL Behring To Present New Data For rIX-FP And rVIII-SingleChain at the 57th American Society of Hematology Annual Meeting & Exposition 12/2/2015 7:50:28 AM
Centers For Medicare And Medicaid Services Extends New Technology Add-On Payment For CSL Behring’s Kcentra For Third Year 9/8/2015 11:33:04 AM
CSL Behring Enrolls First Patient In Global Phase II/III Study Of rVIIa-FP For On-Demand Treatment Of Patients With Hemophilia A Or B With Inhibitors 8/25/2015 7:51:12 AM
Swissmedic Accepts For Review CSL Behring's MAA For rIX-FP For Patients With Hemophilia B 7/28/2015 11:23:36 AM
U.S. FDA Accepts For Review CSL Behring's Biologics License Application For Its Novel Rviii-Singlechain Therapy For Patients With Hemophilia A 7/28/2015 11:21:01 AM